Yuki N, Taki T, Handa S
Department of Biochemistry, Faculty of Medicine, Tokyo Medical and Dental University, Japan.
J Neuroimmunol. 1996 Dec;71(1-2):155-61. doi: 10.1016/s0165-5728(96)00142-7.
N-Acetylgalactosaminyl GD1a (GalNAc-GD1a) is a proposed target molecule for serum antibody in some patients with Guillain-Barré syndrome (GBS) (Kusunoki et al., 1994). We examined autoantibody to GalNAc-GD1a in sera from 58 GBS patients. Eight GBS patients had high IgG anti-GalNAc-GD1a antibody titers, 3 of whom also had high IgM anti-GalNAc-GD1a antibody titers. These 8 patients had experienced gastrointestinal infection before the onset of their neurological symptoms. Campylobacter jejuni was isolated from 4 of them. An absorption test indicated the presence of the GalNAc-GD1a epitope in lipopolysaccharides of C. jejuni. Sera that had anti-GalNAc-GD1a antibody reacted with several acidic glycolipids in bovine peripheral nerve, one of which was identified as N-acetylgalactosaminyl GM1b (GalNAc-GM1b). Serum binding to GalNAc-GM1b was decreased by absorption with GalNAc-GD1a. The presence of GalNAc-GM1b as well as GalNAc-GD1a has been reported in human peripheral nerves. We assume that C. jejuni, which bears the [GalNAc beta 1-4 (NeuAc alpha 2-3) Gal beta 1-3 GalNAc beta 1-] epitope, is the immunogen and that the glycoconjugates with the epitope are target molecules for the autoantibody in peripheral nerves of some GBS patients.
N-乙酰半乳糖胺基GD1a（GalNAc-GD1a）被认为是一些格林-巴利综合征（GBS）患者血清抗体的靶分子（Kusunoki等人，1994年）。我们检测了58例GBS患者血清中针对GalNAc-GD1a的自身抗体。8例GBS患者的IgG抗GalNAc-GD1a抗体滴度较高，其中3例IgM抗GalNAc-GD1a抗体滴度也较高。这8例患者在神经症状发作前曾经历过胃肠道感染。从其中4例患者中分离出空肠弯曲菌。吸收试验表明空肠弯曲菌脂多糖中存在GalNAc-GD1a表位。含有抗GalNAc-GD1a抗体的血清与牛周围神经中的几种酸性糖脂发生反应，其中一种被鉴定为N-乙酰半乳糖胺基GM1b（GalNAc-GM1b）。用GalNAc-GD1a吸收后，血清与GalNAc-GM1b的结合减少。人类周围神经中已报道存在GalNAc-GM1b以及GalNAc-GD1a。我们推测带有[GalNAcβ1-4（NeuAcα2-3）Galβ1-3GalNAcβ1-]表位的空肠弯曲菌是免疫原，并且带有该表位的糖缀合物是一些GBS患者周围神经中自身抗体的靶分子。
